6481. Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial.
作者: Sarah Kattakuzhy.;Chloe Gross.;Benjamin Emmanuel.;Gebeyehu Teferi.;Veronica Jenkins.;Rachel Silk.;Elizabeth Akoth.;Aurielle Thomas.;Charisse Ahmed.;Michelle Espinosa.;Angie Price.;Elana Rosenthal.;Lydia Tang.;Eleanor Wilson.;Soren Bentzen.;Henry Masur.;Shyam Kottilil.; .
来源: Ann Intern Med. 2017年167卷5期311-318页
Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection has resulted in high rates of disease cure; however, not enough specialists currently are available to provide care.
6485. Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.
作者: Shabbir M H Alibhai.;Katherine Zukotynski.;Cindy Walker-Dilks.;Urban Emmenegger.;Antonio Finelli.;Scott C Morgan.;Sebastién J Hotte.;George A Tomlinson.;Eric Winquist.
来源: Ann Intern Med. 2017年167卷5期341-350页
Bone health is a significant concern in men with prostate cancer.
6486. Osteoporosis.
Osteoporosis is a common systemic skeletal disorder resulting in bone fragility and increased fracture risk. However, management of osteoporosis and fracture prevention strategies are often not addressed by primary care clinicians, even in older patients with recent fractures. Evidence-based screening strategies will improve identification of patients who are most likely to benefit from drug treatment to prevent fracture. In addition, careful consideration of when pharmacotherapy should be started and choice of medication and duration of treatment will maximize the benefits of fracture prevention while minimizing potential harms of long-term drug exposure.
6488. Should This Patient Receive an Antidepressant?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Depression is a major public health problem and a common cause of disability. To help physicians choose among available treatment options, the American College of Physicians recently issued a guideline titled "Nonpharmacologic Versus Pharmacologic Treatment of Adult Patients with Major Depressive Disorder." The evidence review done for the guideline found no statistically significant difference in the efficacy of second-generation antidepressants (SGAs) versus most other treatments for this disorder. However, rates of adverse events and discontinuation were generally higher in patients treated with SGAs. This Beyond the Guidelines reviews the guideline and includes a discussion between 2 experts on how they would apply it to a 64-year-old man with depression who is reluctant to begin medication. They review the data on which the guideline is based, discuss the limitations of applying the data to real-world settings, review how they would incorporate patient preferences when making treatment decisions, and outline options for patients in whom first-line therapy has failed.
6498. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis.
作者: Dominik Zenner.;Netta Beer.;Ross J Harris.;Marc C Lipman.;Helen R Stagg.;Marieke J van der Werf.
来源: Ann Intern Med. 2017年167卷4期248-255页
Treatment of latent tuberculosis infection (LTBI) is an important component of tuberculosis (TB) control, and this study updates a previous network meta-analysis of the best LTBI treatment options to inform public health action and programmatic management of LTBI.
6499. Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health.
作者: Beth Han.;Wilson M Compton.;Carlos Blanco.;Elizabeth Crane.;Jinhee Lee.;Christopher M Jones.
来源: Ann Intern Med. 2017年167卷5期293-301页
Despite the continuing epidemic of opioid misuse, data on the prevalence of prescription opioid use, misuse, and use disorders are limited.
6500. Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes: A Cohort Study.
作者: Huabing Zhang.;Jorge Plutzky.;Maria Shubina.;Alexander Turchin.
来源: Ann Intern Med. 2017年167卷4期221-227页
Many patients discontinue statin treatment, often after having a possible adverse reaction. The risks and benefits of continued statin therapy after an adverse reaction are not known.
|